Genetics of the idiopathic inflammatory myopathies

Current Opinion in Rheumatology

Volumn 8, Issue 6, 1996, Pages 514-520

  Garlepp, Michael J ^a  

^a PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B8 ANTIGEN; HLA DR3 ANTIGEN; MITOCHONDRIAL DNA; T LYMPHOCYTE RECEPTOR;

CHROMOSOME 9P; GENE DELETION; GENE LOCATION; GENETIC SUSCEPTIBILITY; HLA TYPING; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MYOPATHY; PATHOGENESIS; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW;

AUTOANTIBODIES; DNA, MITOCHONDRIAL; GENES, IMMUNOGLOBULIN; GENOTYPE; HLA ANTIGENS; HUMANS; INCLUSION BODIES; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED CONNECTIVE TISSUE DISEASE; MYOSITIS; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL;

EID: 0030483059     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199611000-00004     Document Type: Review

References (65)

1. Dalakas MC: Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991, 325:1487-1498.
2. Karpati G, Carpenter S: Pathology of the inflammatory myopathies. Baillieres Clin Neurol 1993, 2:527-556.
3. Hohlfeld R, Goebels N, Engel AG: Cellular mechanisms in inflammatory myopathies. Baillieres Clin Neurol 1993, 2:617-636.
4. Askanas V, Engel WK: New advances in the understanding of sporadic inclusion body myositis and hereditary inclusion-body myopathies. Curr Opin Rheumatol 1995, 7:486-496. This paper gives a detailed account of the histopathologic features of sporadic and hereditary IBM, highlights some of the parallels between IBM and Alzheimer's disease, and provides some theories as to pathogenesis.
5. Campbell RD, Trowsdale J: Map of the human MHC. Immunol Today 1993, 14:349-352.
6. Rammensee H-G, Friede T, Stevanovic S: MHC ligands and peptide motifs: first listing. Immunogenetics 1995, 41:178-228.
7. Jorgensen JL, Reay PA, Erich EW, Davis MM: Molecular components of T cell recognition. Annu Rev Immunol 1992, 10:835-873.
8. Nossal GJV: Negative selection of lymphocytes. Cell 1994, 76:229-239.
9. Altmann DM, Sansom D, Marsh SGE: What is the basis for HLA-DQ associations with autoimmune disease? Immunol Today 1991, 12:267-270.
10. Zhang WJ, Degli-Esposti MA, Cobain TJ, Cameron PU, Christiansen FT, Dawkins RL: Differences in gene copy number carried by different MHC ancestral haplotypes: quantitation after physical separation of haplotypes by pulsed field gel electrophoresis. J Exp Med 1990, 171:2101-2110.
11. Garlepp MJ: Immunogenetics of inflammatory myopathies. Baillieres Clin Neurol 1992, 2:579-597.
12. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW: A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991, 70:360-374.
13. Dawkins RL, Christiansen FT, Kay PH, Garlepp M, McCluskey J, Hollingsworth PN, Zilko PJ: Disease associations with complotypes, supratypes and haplotypes. Immunol Rev 1983, 70:5-22.
14. Carroll GJ, Will RK, Peter JB, Garlepp MJ, Dawkins RL: Penicillamine induced polymyositis and dermatomyositis. J Rheumatol 1987, 14:995-1001.
15. Taneja V, Mehra N, Singh YN, Kumar A, Malaviya A, Singh RR: HLA-D region genes and susceptibility to D-penicillamine induced myositis. Arthritis Rheum 1990, 33:1445-1447.
16. Reveille JD, Targoff IN, Mimori T, Nguyen HC, Goldstein R, Arnett FC: MHC class II alleles associated with myositis. Arthritis Rheum 1992, 35:S84.
17. Miller FW: Myositis-specific antibodies: touchstones for understanding the inflammatory myopathies. JAMA 1993, 270:1846-1849.
18. Targoff IN: Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol 1993, 100:116S-123S.
19. Goldstein R, Duvic M, Targoff IN, Reichlin M, McMenemy AM, Reveille JD, Warner NB, Pollack MS, Arnett FC: HLA-D region genes associated with autoantibody responses to histidyl-transfer RNA synthetase (Jo-1) and other translation-related factors in myositis. Arthritis Rheum 1990, 33:1240-1248.
20. Mierau R, Dick T, Bartz-Bazzanella P, Keller E, et al.: Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum 1996, 39:868-876. A molecular genetic study suggesting the first MHC amino acid localization as a risk factor for a myositis-specific autoantibody.
21. Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M: Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum 1992, 35:449-456.
22. Hirakata M, Nakamura K, Fujii T, Okano Y, Mimori T, Takeda Y, Hardin JA, Akizuki M: Clinical and immunogenetic features of anti-SRP autoantibodies in Japanese patients. Arthritis Rheum 1995, 38:S321.
23. Hirakata M, Suwa A, Nakamura K, Mimori T, Akizuki M, Takeda Y, Hardin JA: Myositis-specific antibodies are associated with HLA class II alleles in Japanese patients. Arthritis Rheum 1995, 38:S321.
24. Hirakata M, Nakamura K, Okano Y, Suwa A, Inada S, Akizuki M, Hardin JA: Anti-alanyl tRNA synthetase (PL-12) antibodies are associated with interstitial lung diseases in Japanese patients. Arthritis Rheum 1995, 38:S321.
25. Marguerie C, Bunn CC, Copier J, Bernstein RM, Gilroy JM, Black CM, So AK, Walport MJ: The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine 1992, 71:327-336.
26. Arnett FC: HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 1995, 12:107-128.
27. Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA: Serum autoantibody to the nucleolar antigen Pm-Scl. Arthritis Rheum 1992, 35:1211-1217.
28. Serjeantson SW, Kohonen-Corish MR, Rowley MJ, Mackay IR, Knowles W, Zimmet P: Antibodies to glutamic acid decarboxylase are associated with HLA-DR genotypes in both Australians and Asians with type 1 (insulin-dependent) diabetes mellitus. Diabetalogia 1992, 35:996-1001.
29. Garlepp MJ, Laing B, Zilko PJ, Ollier W, Mastaglia FL: HLA associations with inclusion body myositis. Clin Exp Immunol 1994, 98:40-45.
30. Dalakas MC, Illa I: Common variable immunodeficiency and inclusion body myositis: a distinct myopathy mediated by natural killer cells. Ann Neurol 1995, 37:806-810.
31. Garlepp MJ, Mastaglia FL: Inclusion body myositis. J Neurol Neurosurg Psychiatry 1996, 60:251-255. Discusses the pathologic and genetic features of sporadic IBM and possible relationships between the T cell infiltrate and the inclusion bodies.
32. Serratrice G: Is inclusion body myositis truly a form of myositis? Rev Rhum Ed Tr 1993, 60:187-188.
33. Barohn RJ, Amato AA, Sahenk Z, Kissel JT, Mendell JR: Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995, 45:1302-1304. These data, from a study of patients treated with steroids, illustrate a dissociation between the inflammatory response in the muscle of sporadic IBM and formation of vacuolated fibers and disease progression.
34. Mantegazza R, Andreetta F, Bernasconi P, Baggi F, Oksenberg JR, Simoncini O, Mora M, Cornelio F, Steinman L: Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. J Clin Invest 1993, 91:2880-2886.
35. Lindberg C, Oldfors A, Tarkowski A: Restricted use of T cell receptor V genes in endomysial infiltrates of patients with inflammatory myopathies. Eur J Immunol 1994, 24:2659-2663.
36. O'Hanlon TP, Miller FW: T cell-mediated immune mechanisms in myositis. Curr Opin Rheumatol 1995, 7: 503-509. A detailed review of TCR V gene usage in inflammatory muscle diseases.
37. + T cells.
38. O'Hanlon TP, Dalakas MC, Plotz PH, Miller FW: The αβ T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes. J Autoimmun 1994, 7:321-333.
39. Fyhr I-M, Moslemi A-R, Tarkowski A, Lindberg C, Oldfors A: Limited T-cell receptor V gene usage in inclusion body myositis. Scand J Immunol 1996, 43:109-114.
40. Maury CPJ: Molecular pathogenesis of β-amyloldosis in Alzheimer's disease and other cerebral amyloidoses. Lab Invest 1995, 72:4-16.
41. Sivakumar K, Cervenakova L, Dalakas MC, Leon-Monzon M, Isaacson SH, Nagle JW, Vasconcelos O, Goldfarb LG: Exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy. Ann Neurol 1995, 38:267-269.
42. DeArmond SJ, Prusiner SB: Etiology and pathogenesis of prion diseases. Am J Pathol 1995, 146:785-811.
43. Roses AD: Apolipoprotein E affects the rate of Alzheimer disease expression: β-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol 1994, 53:429-437.
44. Garlepp MJ, Tabarias H, van Bockxmeer FM, Zilko PJ, Laing B, Mastaglia FL: Apolipoprotein E ε4 in inclusion body myositis. Ann Neurol 1995, 38:957-959.
45. Harrington CR, Anderson JR, Chan KK: Apolipoprotein E type ε4 allele frequency is not increased in patients with sporadic inclusion body myositis. Neurosci Lett 1995, 183:35-38.
46. Askanas V, Engel WK, Mirabella M, Weisbarger KH, Saunders AM, Roses AD, McFerrin J: Apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion body myopathy. Ann Neurol 1996, 40:264.
47. Sherrington R, Rogeav EI, Liang Y, Rogeava EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375:754-760.
48. Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST: APOE*4-associated Alzhelmer's disease risk is modified by α1-antichymotrypsin polymorphism. Nature Genet 1995, 10:486-488.
49. Mitrani-Rosenbaum S, Argov Z, Blumenfeld A, Seidman CE, Seidman JG: Hereditary inclusion body myopathy maps to chromosome 9p1-q1. Hum Mol Genet 1996, 5:159-164. The first mapping of a gene predisposing to inclusion body myopathy.
50. Rifai Z, Welle S, Kamp C, Thornton CA: Ragged red fibers in normal aging and inflammatory myopathy. Ann Neurol 1995, 37:24-29.
51. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP: Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713. A timely update including proposed diagnostic criteria and a review of the histopathology, mitochondrial lesions, immunologic features, and treatment of sporadic and hereditary IBM.
52. Oldfors A, Moslemi A-R, Fhyr I-M, Holme E, Larsson N-G, Lindberg C: Mitochondrial DNA deletions in muscle fibers in inclusion body myositis. J Neuropathol Exp Neurol 1995, 54:581-587. A thorough analysis of the mitochondrial DNA deletions in the muscle of patients with sporadic IBM. Deletions were detected in all 20 patients and all showed evidence of a common 5-kb deletion, although some patients showed multiple deletions. Single fibers within individual patients had only one type of deletion. Discusses the origin of these deletions and their relevance to the pathogenesis of IBM.
53. Santorelli FM, Sciacco M, Tanji K, Shanske S, Vu TH, Golzi V, Griggs RC, Mendell JR, Hays AP, Bertorini TE, Pestronk A, Bonilla E, Di Mauro S: Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients. Ann Neurol 1996, 39:902-908. A larger study of mitochondrial DNA lesions in IBM in which deletions were detected in the muscle of 73% of patients. Discusses the origin of these deletions and their relevance to the pathogenesis of IBM.
54. Horvath R, Fu K, Genge A, Karpati G, Shoubridge EA: Mitochondrial DNA abnormalities and the pathogenesis of sporadic inclusion-body myositis. Neurology 1996, 46:A117.
55. Suomalainen A, Kaukonen J, Amati P, Timonen R, Haltia M, Weissenbach J, Zevioni M, Somer H, Peltonen L: An autosomal dominant locus predisposing to deletions of mitochondrial DNA. Nature Genet 1995, 9:146-151.
56. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR: Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972, 52:148-159.
57. Genth E, Zamowski H, Mierau R, Wohltmann D, Hartl PW: HLA-DR4 and Gm (1,3;5,21) are associated with U1-nRNP antibody positive connective tissue disease. Ann Rheum Dis 1987, 46:189-196.
58. Hoffman RW, Rettenmaier LJ, Takeda Y, Hewett JH, Pettersson I, Nyman U, Luger AM, Sharp GC: Human autoantibodies against the 70-kd polypeptide of U1 small nuclear RNP are associated with HLA-DR4 among connective tissue disease patients. Arthritis Rheum 1990, 33:666-673.
59. Ruuska P, Hameenkorpi R, Forsberg S, Julkunen H, Makitalo R, Ilonen J, Tiilikainen A: Differences in HLA antigens between patients with mixed connective tissue disease and systemic lupus erythematosus. Ann Rheum Dis 1992, 51:52-55.
60. Kaneoka H, Hsu K-C, Takeda Y, Sharp GC, Hoffman RW: Molecular genetic analysis of HLA-DR and HLA-DQ genes among anti-U1-70-kd autoantibody positive connective tissue disease patients. Arthritis Rheum 1992, 35:83-94.
61. Nishikai M, Sekiguchi S: Relationship of autoantibody expression and HLA phenotype in Japanese patients with connective tissue diseases. Arthritis Rheum 1985, 28:579-581.
62. Dong R-P, Kimura A, Hashimoto H, Akizuki M, Nishimura Y, Sasazuki T: Difference in HLA-linked genetic background between mixed connective tissue disease and systemic lupus erythematosus. Tissue Antigens 1993, 41:20-25.
63. Enz LA, Love LA, Targoff IN, Pandey JP, Miller FW: Associations among Gm phenotypes, HLA alleles, and myositis-specific autoantibodies (MSA) in idiopathic inflammatory myopathy (IIM). Arthritis Rheum 1992, 35:832.
64. Genth E, Zarnowski H, Mierau R, Wohltmann D, Hartl PW: HLA-DR4 and Gm (1,3;5,21) are associated with U1-nRNP antibody positive connective tissue disease. Ann Rheum Dis 1987, 46:189-196.
65. Leon-Monzon M, Dalakas MC: Diversity of T-cell receptor gene families in the endomysial lymphocytes of patients with sporadic inclusion-body myositis. Neurology 1996, 46:A115.